The invention provides efficient methods for combining single-substitution libraries of nucleic acids that span and encode proteins of interest and for selecting resultant mutant proteins after expression which have improved properties or characteristics.
C40B 30/04 - Procédés de criblage des bibliothèques en mesurant l'aptitude spécifique à se lier à une molécule cible, p.ex. liaison anticorps-antigène, liaison récepteur-ligand
C12N 15/10 - Procédés pour l'isolement, la préparation ou la purification d'ADN ou d'ARN
C07K 1/04 - Procédés généraux de préparation de peptides sur des supports
C07K 16/00 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux
C40B 10/00 - CHIMIE COMBINATOIRE; BIBLIOTHÈQUES, p.ex. CHIMIOTHÈQUES Évolution moléculaire dirigée des macromolécules, p.ex. ARN, ADN ou protéines
C40B 40/02 - Bibliothèques contenues ou présentées dans des micro-organismes, p.ex. des bactéries ou des cellules animales; Bibliothèques contenues ou présentées dans des vecteurs, p.ex. des plasmides; Bibliothèques contenant uniquement des micro-organismes ou des vecteurs
C40B 40/10 - Bibliothèques comprenant des peptides ou des polypeptides ou leurs dérivés
The invention is directed to novel antibody binding compounds specific for the human B7H3 and uses of such compounds for diagnostic and therapeutic purposes.
C07K 16/28 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
The invention provides efficient methods for combining single-substitution libraries of nucleic acids that span and encode proteins of interest and for selecting resultant mutant proteins after expression which have improved properties or characteristics. Specifically, the methods comprising synthesizing a single substitution library for each of a plurality of domains of a protein; expressing separately each member of each single substitution library as a pre-candidate protein; selecting members of each single substitution library which encode pre-candidate proteins which exhibit an improvement in the one or more predetermined characteristics to form a selected library; shuffling members or the selected libraries in a PCR to produce a combinatorial shuffled library; expressing members of the shuffled library as candidate proteins; and selecting mutant proteins which have improved properties or characteristics.
C40B 30/04 - Procédés de criblage des bibliothèques en mesurant l'aptitude spécifique à se lier à une molécule cible, p.ex. liaison anticorps-antigène, liaison récepteur-ligand
C12N 15/10 - Procédés pour l'isolement, la préparation ou la purification d'ADN ou d'ARN
C07K 1/04 - Procédés généraux de préparation de peptides sur des supports
C07K 16/00 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux
C40B 10/00 - CHIMIE COMBINATOIRE; BIBLIOTHÈQUES, p.ex. CHIMIOTHÈQUES Évolution moléculaire dirigée des macromolécules, p.ex. ARN, ADN ou protéines
C40B 40/02 - Bibliothèques contenues ou présentées dans des micro-organismes, p.ex. des bactéries ou des cellules animales; Bibliothèques contenues ou présentées dans des vecteurs, p.ex. des plasmides; Bibliothèques contenant uniquement des micro-organismes ou des vecteurs
C40B 40/10 - Bibliothèques comprenant des peptides ou des polypeptides ou leurs dérivés
The present invention is directed to novel Anti-TNFα antibody binding compounds and methods of using the same. Anti-TNFα antibody binding compounds of the invention comprise novel heavy chain immunoglobulin polypeptides of portions thereof. In some embodiments, the invention also includes pharmaceutical compositions comprising at least one Anti-TNFα antibody binding compound. The invention further provides the use of an Anti-TNFα antibody binding compound of the invention in the preparation of a medicament for the therapeutic and/or prophylactic treatment of a disorder.
C07K 16/00 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux
C07K 16/24 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des cytokines, des lymphokines ou des interférons
The invention is directed to novel antibody binding compounds specific for the human B7H3 and uses of such compounds for diagnostic and therapeutic purposes.
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
C07K 16/28 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
C07K 16/30 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire provenant de cellules de tumeurs
The invention provides efficient methods for combining single-substitution libraries of nucleic acids that span and encode proteins of interest and for selecting resultant mutant proteins after expression which have improved properties or characteristics. Specifically, the methods comprising synthesizing a single substitution library for each of a plurality of domains of a protein; expressing separately each member of each single substitution library as a pre-candidate protein; selecting members of each single substitution library which encode pre-candidate proteins which exhibit an improvement in the one or more predetennined characteristics to form a selected library; shuffling members or the selected libraries in a PCR to produce a combinatorial shuffled library; expressing members of the shuffled library as candidate proteins; and selecting mutant proteins which have improved properties or characteristics.
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
C40B 40/02 - Bibliothèques contenues ou présentées dans des micro-organismes, p.ex. des bactéries ou des cellules animales; Bibliothèques contenues ou présentées dans des vecteurs, p.ex. des plasmides; Bibliothèques contenant uniquement des micro-organismes ou des vecteurs
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir des acides nucléiques
C07H 21/04 - Composés contenant au moins deux unités mononucléotide comportant chacune des groupes phosphate ou polyphosphate distincts liés aux radicaux saccharide des groupes nucléoside, p.ex. acides nucléiques avec le désoxyribosyle comme radical saccharide
The present invention is directed to novel Anti-TNFα antibody binding compounds and methods of using the same. Anti-TNFα antibody binding compounds of the invention comprise novel heavy chain immunoglobulin polypeptides of portions thereof. In some embodiments, the invention also includes pharmaceutical compositions comprising at least one Anti-TNFα antibody binding compound. The invention further provides the use of an Anti-TNFα antibody binding compound of the invention in the preparation of a medicament for the therapeutic and/or prophylactic treatment of a disorder.
C07K 16/24 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des cytokines, des lymphokines ou des interférons
The present invention is directed to novel SD1 antibody binding compounds and methods of using (he same. SD1 antibody binding compounds of the invention comprise novel heavy chain immunoglobulin polypeptides of portions thereof.
C07K 16/30 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire provenant de cellules de tumeurs
G01N 33/574 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet pour le cancer
9.
NOVEL ANTI-B7H3 BINDING COMPOUNDS AND USES THEREOF
The invention is directed to novel antibody binding compounds specific for the human B7H3 and uses of compounds for diagnostic and therapeutic purposes.
C07K 16/30 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire provenant de cellules de tumeurs
10.
PARALLEL DETERMINATION OF COMPETITIVE BINDING AND TARGET SPECIFICITY OF A BINDING COMPOUND LIBRARY
The invention is directed to a method for analyzing the competitive binding and target (or ligand) specificity of large numbers of candidate binding compounds with respect to a predetermined reference compound. That is, the invention provides a method for essentially conducting a massively parallel ELISA on each member of an entire library of candidate binding compounds at the same time. Instead of determining binding characteristics from a series of colorimetric or fluorometric readouts, such characteristics are determined from a series of frequencies of bound and unbound library members which, in turn, are determined by high- throughput sequencing of their encoding nucleic acids. In one aspect, predetermined reference compounds are proteins and candidate binding compounds are members of a mutant library based on, or related to, the predetermined reference compound.
C40B 30/04 - Procédés de criblage des bibliothèques en mesurant l'aptitude spécifique à se lier à une molécule cible, p.ex. liaison anticorps-antigène, liaison récepteur-ligand
G01N 33/53 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet
The invention is directed to methods for obtaining statistically significant information about how structural elements of proteins, e.g. position and identity of amino acid residues in binding domains, relate to functional properties of interest, such as binding affinity, specificity, and the like. In some embodiments, such information is collected by reacting under binding conditions a focused library of candidate nucleic acid-encoded binding compounds with a ligand, so that complexes form between the ligand and a portion of the candidate binding compounds ("binders"). Samples of binders and non-binders are then decoded by high throughput nucleic acid sequencing to give statistically significant data about the binding properties of substantially all of the candidate binding compounds, permitting them to be ranked by their respective affinities or dissociation constants. A reference compound, such as a pre-existing antibody, may be included in the reaction to identify candidates with similar or improved binding characteristics that have additional desirable characteristics, such as higher solubility, reduced immunogenicity, higher stability, or the like.
G01N 33/53 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet
C40B 30/04 - Procédés de criblage des bibliothèques en mesurant l'aptitude spécifique à se lier à une molécule cible, p.ex. liaison anticorps-antigène, liaison récepteur-ligand
brevets
